The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
Open accessAbstract
BACKGROUND: TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in humans has not been evaluated. METHODS AND FINDINGS: In this single-arm phase 2 trial, adults with laboratory-confirmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d. On days when trial enrolment capacity was reached, patients were enrolled into a concurrent observational cohort. The primary outcome was survival to day 14 after admission, excluding patients who died within 48 h of admission. After 14 adults with EVD had received TKM-130803, the pre-specified futility boundary was reached, indicating a probability of survival to day 14 of ≤0.55, and enrolment was stopped. Pre-treatment geometric mean Ebola virus load in the 14 TKM-130803 recipients was 2.24 × 109 RNA copies/ml plasma (95% CI 7.52 × 108, 6.66 × 109). Two of the TKM-130803 recipients died within 48 h of admission and were therefore excluded from the primary outcome analysis. Of the remaining 12 TKM-130803 recipients, nine died and three survived. The probability that a TKM-130803 recipient who survived for 48 h will subsequently survive to day 14 was estimated to be 0.27 (95% CI 0.06, 0.58). TKM-130803 infusions were well tolerated, with 56 doses administered and only one possible infusion-related reaction observed. Three patients were enrolled in the observational cohort, of whom two died. CONCLUSIONS: Administration of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adult patients with severe EVD was not shown to improve survival when compared to historic controls. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201501000997429.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections
WHO Ebola Response Team (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411100 · Cited by 1,674
Cited by
Jacob, S. T., Crozier, I., Fischer, W. A., Hewlett, A., Kraft, C. S., Vega, M.-A. D. L., Soka, M. J., Wahl, V., Griffiths, A., Bollinger, L., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0147-3 · Cited by 664
Lipid nanoparticles for nucleic acid delivery: Current perspectives
Samaridou, E., Heyes, J., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 583
siRNA: Mechanism of action, challenges, and therapeutic approaches
Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. M., Aljabali, A. A. A., & Awidi, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174178 · Cited by 441
Malvy, D., McElroy, A. K., de Clerck, H., Günther, S., & van Griensven, J. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33132-5 · Cited by 419
MicroRNA Regulation of RNA Virus Replication and Pathogenesis
Trobaugh, D. W., & Klimstra, W. B. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.11.003 · Cited by 394
Metadata
- Authors
- Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., Brooks, T. J. G., Simpson, A. J. H., Goodfellow, I., Thorne, L., Arias, A., Merson, L., Castle, L., Howell-Jones, R., Pardinaz-Solis, R., Hope-Gill, B., Ferri, M., Grove, J., Kowalski, M., Stepniewska, K., Lang, T., Whitehead, J., Olliaro, P., Samai, M., Horby, P. W., & for the RAPIDE-TKM trial team
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-19
- Volume
- 13
- Issue
- 4
- Pages
- e1001997
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2336471513
- Cited by
- 165
- References
- 2
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1001997
- The paper
- Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., Brooks, T. J. G., Simpson, A. J. H., Goodfellow, I., Thorne, L., Arias, A., Merson, L., Castle, L., Howell-Jones, R., Pardinaz-Solis, R., . . . for the RAPIDE-TKM trial team. (2016). Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1001997
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.